Feedback
Settings

Settings

Goto Application

281,128 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 28,113
1.20260028661COMPOUNDS AND METHODS RELATING TO TESTING FOR LYSOSOMAL STORAGE DISORDERS
US - 29.01.2026
Int.Class C12Q 1/34
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
34involving hydrolase
 Appl.No 19174322 Applicant University of Washington through its Center for Commercialization Inventor Alexander Cherkassky

Provided are substrates and methods for detecting enzymatic activity of various lysosomal storage enzymes. The molecules may be used as substrates with improved solubility.

2.WO/2026/025019SYNTHESIS OF MACROBICYCLIC THIOLINCOSAMINES
WO - 29.01.2026
Int.Class C07H 15/26
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
26Acyclic or carbocyclic radicals, substituted by hetero rings
 Appl.No PCT/US2025/039234 Applicant PRESIDENT AND FELLOWS OF HARVARD COLLEGE Inventor TRESCO, Ben, Calhoun
Provided herein are methods for preparing macrobicyclic thiolincosamines and associated synthetic intermediates. These routes allow access to lincosamide analogues, which are useful for the treatment and prevention of infectious diseases. The methods are scalable and provide access to multi-gram quantities of the aminooctose (northern) fragments of the lincosamide analogues.
3.WO/2026/021564FLAVONOID COMPOUND, AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF
WO - 29.01.2026
Int.Class C07D 311/30
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
311Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
02ortho- or peri-condensed with carbocyclic rings or ring systems
04Benzo pyrans, not hydrogenated in the carbocyclic ring
22with oxygen or sulfur atoms directly attached in position 4
26with aromatic rings attached in position 2 or 3
28with aromatic rings attached in position 2 only
30not hydrogenated in the hetero ring, e.g. flavones
 Appl.No PCT/CN2025/110546 Applicant SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY COMPANY LIMITED Inventor ZHANG, Qingwen
Disclosed in the present invention are a flavonoid compound, and a preparation method therefor, a pharmaceutical composition comprising same, and a use thereof. The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof. The compound of the present invention has broad-spectrum activity against diseases caused by infection with α coronaviruses (e.g., PEDV) and δ coronaviruses (e.g., PDCoV), and/or the compound of the present invention has biological activity in treating tumors.
4.20260028615EXTRACTION METHOD FOR NUCLEIC ACIDS
US - 29.01.2026
Int.Class C12N 15/10
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
10Processes for the isolation, preparation or purification of DNA or RNA
 Appl.No 18997217 Applicant Siemens Healthcare Diagnostics Inc. Inventor Ishita CHAKRABORTY

A method (100) of extracting nucleic acids is disclosed. The method includes receiving a sample containing nucleic acids to be extracted. The method (100) includes lysing cells in the sample to release the nucleic acids. The method (100) also includes introducing the released nucleic acids to a substrate, wherein the nucleic acids bind to the substrate. The method (100) includes washing the substrate bound to the nucleic acids and eluting the nucleic acids from the substrate. The introducing of the released nucleic acids to the substrate. the washing of the substrate bound to the nucleic acids, and the eluting of the nucleic acids are performed in a pipette tip.

5.WO/2026/022256GALLIUM-APRAMYCIN COMPLEXES, METHODS OF PREPARATION THEREOF AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
WO - 29.01.2026
Int.Class A61K 31/7036
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7034attached to a carbocyclic compound, e.g. phloridzin
7036having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
 Appl.No PCT/EP2025/071246 Applicant INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE Inventor TEWES, Frédéric
The present invention relates to novel complexes of gallium and apramycin. The complexes according to the invention are useful in the treatment of bacterial infections. The complexes are particularly suitable for administration by inhalation when they are provided in the form of spray-dried particles.
6.WO/2026/022036METHOD FOR MANUFACTURING L-FUCOSE POWDER BY SPRAY-DRYING AND SPRAY-DRIED L-FUCOSE POWDER
WO - 29.01.2026
Int.Class A23P 10/43
AHUMAN NECESSITIES
23FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; PREPARATION, TREATMENT OR PRESERVATION THEREOF
PSHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
10Shaping or working of foodstuffs characterised by the products
40Making free-flowing powder or instant powder, i.e. powder which is reconstituted rapidly when liquid is added
43using anti-caking agents or agents improving flowability, added during or after formation of the powder
 Appl.No PCT/EP2025/070686 Applicant CHR. HANSEN A/S Inventor VALENTINER, Borge
Disclosed is a spray-dried powder consisting essentially of L-fucose and an additive that enables spray-drying of L-fucose, said additive being maltodextrin or skimmed milk powder, a method of spray-drying L-fucose to obtain said spray-dried powder, and the use of the spray-dried powder for manufacturing nutritional compositions or pharmaceutical compositions.
7.20260028640ANTIFUNGAL PLANT PROTEINS, PEPTIDES, AND METHODS OF USE
US - 29.01.2026
Int.Class C12N 15/82
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
82for plant cells
 Appl.No 19287263 Applicant Donald Danforth Plant Science Center Inventor Dilip Shah

Provided are transgenic plants expressing MtDef5 antifungal proteins and peptides exhibiting high levels of resistance to susceptible fungi. Such transgenic plants contain a recombinant DNA construct comprising a natural or heterologous signal peptide sequence operably linked to a nucleic acid sequence encoding these molecules. Also provided are methods of producing such plants, methods of protecting plants against susceptible fungal infection and damage, as well as compositions that can be applied to the locus of plants, comprising microorganisms expressing these molecules, or these molecules themselves, as well as pharmaceutical compositions containing these molecules. Human and veterinary therapeutic use of MtDef5 antifungal proteins and peptides to treat susceptible fungal infections are also encompassed by the invention.

8.WO/2026/021467STEREOSPECIFIC LINKAGES DOUBLE STRANDED RNA AGENTS AND COMPOSITIONS
WO - 29.01.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No PCT/CN2025/110030 Applicant SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. Inventor SHU, Dongxu
The present disclosure provides a double-stranded nucleic acid, compositions, and methods relating thereto. The present disclosure encompasses the recognition that structural elements of double stranded nucleic acid, such as stereochemistry of backbone chiral centers (chiral internucleonic linkages), and/or patterns thereof, specially, double-stranded nucleic acid having one or more chirally enriched phosphorothioate internucleotide linkages can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, stability, delivery, etc. The present disclosure also provides methods for treatment of diseases using provided double stranded nucleic acid compositions, for example, in RNA interference.
9.20260028367DOT1L DEGRADERS AND USES THEREOF
US - 29.01.2026
Int.Class C07H 19/16
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
16Purine radicals
 Appl.No 19235208 Applicant DANA-FARBER CANCER INSTITUTE, INC. Inventor Scott Armstrong

Provided herein are bifunctional compounds with a moiety or domain that is a binder of the ubiquitin receptor RPN13 and another moiety or domain that is a binder of a target protein DOT1L to induce degradation of DOT1L. Also provided are pharmaceutical compositions comprising the bifunctional compounds, and methods of treating and/or preventing diseases (e.g., proliferative diseases, such as cancers). Provided also are methods of inducing the degradation of DOT1L by administering a bifunctional compound or composition described herein, wherein one domain of the bifunctional compound is a binder of the ubiquitin receptor RPN13 and another domain of the compound is a binder of the target protein DOT1L in a subject.

embedded image

10.WO/2026/024784COMPOSITION AND METHOD FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES
WO - 29.01.2026
Int.Class A61K 31/203
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
19Carboxylic acids, e.g. valproic acid
20having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid
203Retinoic acids
 Appl.No PCT/US2025/038754 Applicant MASTERY BIOTECH CO., LTD. Inventor LIN, Bo-Lin
Provided are methods for prevention or treatment of neurodegenerative diseases. Also provided are compositions for use in preventing or treating neurodegenerative diseases.
# -